NEW YORK, NY / ACCESSWIRE / May 24, 2018 / U.S. markets rebounded modestly on Wednesday, following the release of Fed's minutes of the meeting, which suggest that the central bank will be slightly dovish in raising interest rate. The Dow Jones Industrial Average gained 0.21 percent to close at 24,886.81, while the S&P 500 Index increased 0.32 percent to close at 2,733.29. The Nasdaq Composite Index climbed 0.64 percent to close at 7,425.96.

"The 2% inflation target is not sacrosanct, the current environment required more flexibility from the Fed to let the economy grow at a faster pace," said Quincy Krosby, chief market strategist at Prudential Financial. "The minutes from the Fed suggest they are willing to keep rates lower for longer to allow the economy to recover," Krosby added.

RDI Initiates Coverage on:

CRISPR Therapeutics AG
https://rdinvesting.com/news/?ticker=CRSP

Align Technology, Inc.
https://rdinvesting.com/news/?ticker=ALGN

CRISPR Therapeutics' stock jumped 9.11% Wednesday, to close the day at $69.57. The stock recorded a trading volume of 1,928,355 shares, which was above its three months average volume of 1,355,758 shares. In the last year, CRISPR Therapeutics' shares have traded in a range of 13.50 - 69.90. The share price has gained 415.33% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $52.51 is above its 200-day moving average of $38.09. Shares of CRISPR Therapeutics have gained roughly 40.26 percent in the past month and are up 196.29 percent year-to-date.

Access RDI's CRISPR Therapeutics AG Research Report at:
https://rdinvesting.com/news/?ticker=CRSP

On Wednesday, shares of Align Technology recorded a trading volume of 1,176,599 shares, which was above the three months average volume of 955,840 shares. The stock ended the day 3.47% higher at $308.20. The share price has fallen 0.15% from its 52-week high with a 52-week trading range of 138.71 - 308.67. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $266.38 is above its 200-day moving average of $255.13. Shares of the company are trading at a Price to Earnings ratio of 108.90. Shares of Align Technology have gained roughly 24.68 percent in the past month and are up 38.71 percent year-to-date.

Access RDI's Align Technology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ALGN

Our Actionable Research on CRISPR Therapeutics AG (NASDAQ:CRSP) and Align Technology, Inc. (NASDAQ:ALGN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com